Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 2016

View Archived Issues

Phase I studies show target engagement, acute GI symptoms with NexVax2 in HLA DQ2.5 celiac disease

BioRap and Pfizer enter agreement to develop new immunomodulators

NanoViricides enters partnership to further FluCide-I program

Grunenthal licenses European and Latin American rights to Zurampic from AstraZeneca

Incyte establishes collaboration to conduct several Moffitt blood cancer research programs

Dermira reports topline results from pivotal trials of DRM-04 for primary axillary hyperhidrosis

RegeneRx Biopharmaceuticals and Lee's Pharmaceutical accelerate development of RGN-259

Novartis plans phase III trials of subcutaneous ofatumumab in relapsing MS

BGN gene defects may cause an X-linked syndromic form of severe TAAD

FDA grants rare pediatric disease designation to Therabron's rhCC10

Corcept Therapeutics updates status of cortisol modulation programs in oncology

University College Cardiff Consultants patents AR modulators

Merck & Co. discloses sGC activators

Takeda Pharmaceutical describes GPR139 agonists

Eli Lilly and Company develops PKC inhibitors

Esteve presents dual sigma1 and mu-opioid receptor ligands

Pharosgen patent reveals anticancer agents

Shire completes combination with Baxalta

Deutetrabenazine shows promise for the treatment of for TD-related abnormal involuntary movements

Vectura's phase I trial of VR-942 meets primary objective

CSF exposure and proof of mechanism seen for cognitive impairment treatment BI-425809

Bellicum Pharmaceuticals enters research agreement with LUMC

Treos Bio developing precision cancer vaccines paired to companion diagnostics

Kiadis plans European MAA for ATIR-101

Astellas and Medivation plan phase III trial of enzalutamide for triple-negative breast cancer

Nektar Therapeutics reaches agreement with Daiichi Sankyo Europe for Onzeald

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...